HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The firm will use the proceeds to advance preclinical studies of its small interfering RNA therapy in KRAS-mutant colorectal and pancreatic cancer.

The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.

The firm will use the proceeds to advance BE-101 for hemophilia B through clinical proof-of-concept testing and BE-102 for hypophosphatasia into the clinic.

The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.